GNFTF News and Press, Genfit Ord From 04/07/22

Genfit press release (NASDAQ:GNFT): FY GAAP EPS of €1.23. Revenue of €85.58M (+1002.8% Y/Y). Cash and cash equivalents totaled €258.8 million as of December 31, 202. Outlook 2022: Elafibranor in Primary Biliary Cholangitis, commitment for topline data reado...

The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021. Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster. Both early clinical assets address a market with a high medical need and have blockbuster ...

GENFIT SA (GNFT) Q2 2020 Results Conference Call September 30, 2020 04:30 PM ET Company Participants Stefanie Magner - Deputy Director, Legal Affairs Pascal Prigent - CEO Dean Hum - Chief Scientific Officer and COO Conference Call Participants Thomas Smith - SVB Leerink Derek Archila - Stifel...

The following slide deck was published by Genfit SA in conjunction with this Read more ...

Theratechnologies announces positive report for tesamorelin in NASH Theratechnologies Inc. ( THTX ) announced positive data corroborating the impact of tesamorelin in treating HIV-associated nonalcoholic steatohepatitis. The data has been gleaned from a sub-analysis of the Phase 2 study. T...

XBiotech makes a crucial breakthrough in True Human antibodies Development XBiotech Inc. (XBIT) reported that it has made an important breakthrough in the development of True Human antibodies, novel inflammation countering mechanism. This new type of antibody seeks to replace previous-gene...

Investment Thesis Formulating the launch plans well ahead of the approval, Intercept Pharmaceuticals, Inc. ( ICPT ) caught completely off guard when the FDA refused to sign off OCA, a Intercept’s candidate for liver fibrosis in NASH. The agency, however, hasn’t completely ...

Introduction In March, I wrote an article about Genfit (NASDAQ: GNFT ) and the potential of its lead drug candidate Elafibranor in NASH. In my analysis, I underlined the huge upward potential but also underpinned the binary characteristic of the investment case. My recommendation was to ...

Investment Thesis Intercept Pharmaceuticals, Inc. ( ICPT ) is ahead of a potential FDA approval that could unlock a market opportunity worth billions of dollars. Despite the concerns over the side effects, the drug could become the first-ever to treat liver fibrosis in NASH. However, the s...

Introduction It is remarkable how few articles have been published about Genfit ( GNFT) lately on Seeking Alpha. The last articles dated from June and August last year. This is quite remarkable since the company is nearing its make-or-break moment and indicates that investors’ ...